Floatz logo

Eli-002 7P

KRAS G12R

Elicio TherapeuticsPhase 1/2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the KRAS G12R cohort.

Asset / SponsorPhaseRating
Irinotecan
Institut de Recherches Internationales Servier
Phase 1/2CCC
FLUOROURACILUM
Institut de Recherches Internationales Servier
Phase 1/2CCC
Cetuximab
Institut de Recherches Internationales Servier
Phase 1/2CCC
PANITUMUMAB
Institut de Recherches Internationales Servier
Phase 1/2CCC
s241656
Institut de Recherches Internationales Servier
Phase 1/2CCC
Calcium folinate pentahydrate
Institut de Recherches Internationales Servier
Phase 1/2CCC

Same molecule, other indications

Eli-002 7P is also rated in:

NRAS G12DDormant
B
Indicative ·
57 / 100
View asset →
KRAS G12DDormant
CCC
Indicative ·
53 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →